# FATE catalysts: FATE THERAPEUTICS INC PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/fate/catalysts

> FATE THERAPEUTICS INC (FATE) has 2 upcoming catalysts. The next is the FT819 primary completion, July 2029.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, year only, half-year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | FATE THERAPEUTICS INC |
| Ticker | FATE (Nasdaq) |
| SEC CIK | 1434316 |
| SIC | 2836 |
| SEC filings | https://sec-api.dev/companies/fate |

## Cash runway

Cash $139.1M as of 2026-09-30; quarterly burn $27.8M; about 15.0 months of runway at that rate (XBRL company facts, accession 0001193125-26-448543).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Jan 2024 | [FT825 trial start](https://sec-api.dev/pdufa/ft825) | FATE | advanced solid tumors | completed | "In January 2024, we initiated a multi-center, Phase 1 clinical trial of FT825 for the treatment of advanced solid tumors (NCT06241456) alongside our collaborator Ono Pharmaceutical (see "Our Partnership with Ono Pharmaceutical")." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1434316/000119312526073699/fate-20251231.htm)) |
| November 12, 2024 | [FATE THERAPEUTICS INC earnings report](https://sec-api.dev/companies/fate/catalysts) | FATE |  | completed | "Fate Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1434316/000095017024125307/fate-ex99_1.htm)) |
| March 5, 2025 | [FATE THERAPEUTICS INC earnings report](https://sec-api.dev/companies/fate/catalysts) | FATE |  | completed | "Fate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1434316/000095017025033507/fate-ex99_1.htm)) |
| May 13, 2025 | [FATE THERAPEUTICS INC earnings report](https://sec-api.dev/companies/fate/catalysts) | FATE |  | completed | "Fate Therapeutics Reports First Quarter 2025 Financial Results and Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1434316/000095017025070280/fate-ex99_1.htm)) |
| August 7, 2025 | [FATE THERAPEUTICS INC earnings report](https://sec-api.dev/companies/fate/catalysts) | FATE |  | completed | "Fate Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1434316/000119312525178947/d452012dex991.htm)) |
| November 13, 2025 | [FATE THERAPEUTICS INC earnings report](https://sec-api.dev/companies/fate/catalysts) | FATE |  | completed | "Fate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1434316/000119312525279091/fate-ex99_1.htm)) |
| 2026 | [Pathway trial start](https://sec-api.dev/pdufa/pathway) | FATE |  | scheduled | "Building on this momentum, we are also working closely with the FDA under our RMAT designation with the goal of commencing our registrational study for FT819 in SLE and LN in 2026," said Bob Valamehr, Ph.D., MBA," ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1434316/000119312525178947/d452012dex991.htm)) |
| February 26, 2026 | [FATE THERAPEUTICS INC earnings report](https://sec-api.dev/companies/fate/catalysts) | FATE |  | completed | "Fate Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1434316/000119312526073689/fate-ex99_1.htm)) |
| May 13, 2026 | [FATE THERAPEUTICS INC earnings report](https://sec-api.dev/companies/fate/catalysts) | FATE |  | completed | "Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1434316/000119312526220691/fate-ex99_1.htm)) |
| 2H 2026 | [FT839 trial start](https://sec-api.dev/pdufa/ft839) | FATE |  | scheduled | "The Company plans to submit an Investigational New Drug (IND) application to the FDA to support a Phase 1 basket autoimmune study to evaluate FT839 in combination with standard of care therapies across SLE, SSc, AAV, IIM, and rheumatoid arthritis (RA), including without the use of conditioning chemotherapy, and expects to commence enrollment in the Phase 1 study in the second half of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1434316/000119312526220691/fate-ex99_1.htm)) |
| Aug 2026 | [Pathway trial start](https://sec-api.dev/pdufa/pathway) | FATE | refractory moderate-to-severe systemic lupus erythematosus | completed | "In August 2026, we initiated RECLAIM-LN, our Phase 2 clinical trial of FT819 in patients with refractory moderate-to-severe systemic lupus erythematosus (SLE) with lupus nephritis, which we believe may potentially support registration of FT819." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1434316/000119312526458736/d150438d424b5.htm)) |
| August 13, 2026 | [FATE THERAPEUTICS INC earnings report](https://sec-api.dev/companies/fate/catalysts) | FATE |  | completed | "Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1434316/000119312526347984/fate-ex99_1.htm)) |
| November 5, 2026 | [FATE THERAPEUTICS INC earnings report](https://sec-api.dev/companies/fate/catalysts) | FATE |  | completed | "Fate Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1434316/000119312526448530/fate-ex99_1.htm)) |
| July 2029 | [FT819 primary completion](https://sec-api.dev/pdufa/ft819) | FATE | Lupus Nephritis; Systemic Lupus Erythematosus; SLE - Systemic Lupus Erythematosus | scheduled | "NCT07570862 (A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-07-01 (ESTIMATED); Lead Sponsor Fate Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07570862)) |
| Jul to Oct 2029 | [FT819 topline data readout](https://sec-api.dev/pdufa/ft819) | FATE | Lupus Nephritis; Systemic Lupus Erythematosus; SLE - Systemic Lupus Erythematosus | scheduled | "NCT07570862 (A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-07-01 (ESTIMATED); Lead Sponsor Fate Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07570862)) |

## Drugs

- [FT819](https://sec-api.dev/pdufa/ft819): Lupus Nephritis
- [FT825](https://sec-api.dev/pdufa/ft825): advanced solid tumors
- [FT839](https://sec-api.dev/pdufa/ft839): 
- [Pathway](https://sec-api.dev/pdufa/pathway): refractory moderate-to-severe systemic lupus erythematosus, refractory moderate-to-severe systemic lupus erythematosus with lupus nephritis

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/fate/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "FATE catalysts: FATE THERAPEUTICS INC PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/fate/catalysts

```bibtex
@misc{secapidev_companies_fate_catalysts_20261116,
  title        = {FATE catalysts: FATE THERAPEUTICS INC PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/fate/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_fate_catalysts_20261116","title":"FATE catalysts: FATE THERAPEUTICS INC PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/fate/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
